All companies
Visit website
ENGEN BIO
OperatingENGEN BIO, LLC
Founded 2016
A Vaccine and Therapy to Provide Lifetime Protection from Flu Pandemics
Post-money valuation ⓘ
$9.2M
As of Apr 2022 · from ENGEN BIO Stock 1 · pre-money + amount raised, not a traded price
Total raised
$1,207,132
Across 1 round since 2021
Latest share price
$0.586
ENGEN BIO Stock 1 offering price
Financials
FY2018–FY2019 · from SEC filings · hover any figure for its source$0
−$167K
2018
$0
−$460K
2019
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$167,422
-$460,440
Taxes paid
$440
$440
Balance sheet
Cash
$2,447
$163,609
Accounts receivable
$0
$0
Total assets
$2,447
$163,609
Short-term debt
$0
$21,934
Long-term debt
$588,743
$556,411
Total liabilities
$588,743
$578,345
Other
Headcount
—
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$9.2M
post-money
ENGEN BIO Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $1.2M / $1.1MInvestors 915Post-money $9.2M
Reg CF annual-report compliance
Delinquent
Filed 0 of 6 annual reports (FY2020–FY2025)
Missing: 2020, 2021, 2022, 2023, 2024, 2025
915 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001800174Share price $0.586
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.